One of the scFv-fragments targets the tumor antigen and the other scFv-fragment targets FcγRIIIa on NK cells, thereby stimulating the NK cells not via classical engagement of FcγRIIIa but via α-FcγRIIIa binding. This evidence concerns the gene FCGR3A and neoplasm.